B
CSTL icon

Bailard’s Castle Biosciences CSTL Stock Holding History

Bailard’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-11,400
Closed -$260K – 774
2025
Q3 		$260K Buy
+11,400
New +$232K 0.01% 676
2025
Q1 		– Sell
-9,900
Closed -$264K – 759
2024
Q4 		$264K Buy
9,900
+1,100
+13% +$33.5K 0.01% 614
2024
Q3 		$251K Buy
+8,800
New +$224K 0.01% 653

Other funds holding CSTL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
SPPAM
Summit Partners Public Asset Management Boston, Massachusetts $3.72B AUM 162.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return

Bailard's CSTL Position: Q4 2025 in Review

Bailard sold out of Castle Biosciences (CSTL) in Q4 2025, closing a stake of 11,400 shares — an estimated $260K sold.

Bailard first reported a position in CSTL in Q3 2024 and held it in 3 quarters. The position peaked at $264K in Q4 2024. 194 funds tracked by Wall St. Rank hold CSTL as of Q4 2025.

  • Bailard reported no remaining Castle Biosciences position as of Q4 2025 after selling out during the quarter.
  • Bailard sold 11,400 Castle Biosciences shares in Q4 2025, an estimated $260K.
  • Bailard first reported a position in Castle Biosciences in Q3 2024 and held it in 3 quarters.
  • Bailard's Castle Biosciences position peaked at $264K in Q4 2024.
  • 194 funds tracked by Wall St. Rank held Castle Biosciences as of Q4 2025.

Based on Bailard's 13F filing for Q4 2025, filed 4 Feb 2026.